Neon Therapeutics (NTGN) IPO Opens Flat

Today's IPO for Neon Therapeutics (NASDAQ: NTGN) opened for trading at $16 after pricing 6,250,000 shares of common stock at a public offering price of $16.00 per share.

In addition, Neon Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Morgan Stanley, BofA Merrill Lynch and Mizuho Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering.

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens.

You May Also Be Interested In

• Csquare targets up to $1.35 billion in US initial offering
• Wolfe Research Starts LB Pharmaceuticals Inc (LBRX) at Outperform
• BofA Securities Assumes Shopify (SHOP) at Buy